2015 American Transplant Congress
Development of a Targeted Genetic Renal Disease Panel With NexGen Sequencing for Unbiased Testing of Living Kidney Donors for Genetic Kidney Disease
Recent studies indicate that living donors biologically related to their transplant recipient may be at higher risk of ESRD compared to unrelated donors, possibly secondary…2015 American Transplant Congress
Risk of Cause-Specific ESRD in Live Kidney Donors
The purpose of this study is to investigate the risk of developing cause-specific ESRD in live kidney donors over time.METHODS: We studied a cohort of…2015 American Transplant Congress
Impact of Abdominal Aortic Calcification in Living Kidney Donors
Introduction: To assess the association between abdominal aortic calcification (AAC) and renal function of living kidney donor and to evaluate the value of an AAC…2015 American Transplant Congress
Implications of Living Donor Kidney Histology, Volume and Function on Post-Donation GFR
Living kidney donor transplantation is the best modality for treating ESRD as it confers excellent outcomes to patients and it is safe for donors. Postdonation…2015 American Transplant Congress
Impact of Cold Ischemic Time (CIT) and Distance Traveled (DT) on Shipped Kidneys in the OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program (PP)
Background: The success of a national KPD program is predicated on excellent early kidney function and graft survival (GS). As other KPD programs have reported…2015 American Transplant Congress
Recovery After Living Donor Laparoscopic Nephrectomy
Living donors (LDs) require time away from daily activities and work for the surgery and recovery. In general, LDs are counselled that they should be…2015 American Transplant Congress
Hybrid-Natural Orifice Transluminal Endoscopic Surgery (NOTES) for Laparoscopic Donor Nephrectomy Offers Better Postoperative Pain, Cosmesis and Surgical Outcomes Than Transumbilical Single Site Surgery
Department of Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Laparoendoscopic single site donor nephrectomy (LESSDN) via the umbilicus has been our standard care for living donors. Although we have previously reported better cosmetic…2015 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
1Emory University, Atlanta; 2Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…2015 American Transplant Congress
Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
American Transplant Congress abstracts